Pembrolizumab for adjuvant treatment of renal cell carcinoma

Supporting evidence

• Evaluation report

• Final appraisal determination committee papers (PDF 1.18 MB)

  Published:

  19 October 2022

• Appraisal consultation committee papers (PDF 4.1 MB)

  Published:

  19 October 2022